This is an aggregated industry headline. Read the full story at BioPharma Dive →
With $97M, Latus pursues a different kind of Huntington’s gene therapy
The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.
By BioPharma Dive
· May 4, 2026
· via BioPharma Dive
Image: BioPharma Dive
Tags
moneyformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
MoneyFiercePharma ↗
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star hear…
MoneyBriefing
Seaport Therapeutics opted for a $255M Nasdaq IPO over an acquisition, underscoring renewed investor appetite …
MoneyBioPharma Dive ↗
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turna…